98548-82-4 Usage
Uses
Used in Pharmaceutical Industry:
(2E)-4-(Dimethylamino)but-2-enoic acid is used as an active pharmaceutical ingredient for the production of certain medications. Its unique chemical structure allows it to interact with biological targets, making it a valuable component in the development of new drugs.
Used in Organic Synthesis:
In the field of organic synthesis, (2E)-4-(Dimethylamino)but-2-enoic acid serves as a reagent in various chemical reactions. Its carboxylic acid group and double bond enable it to participate in a range of reactions, such as esterification, amidation, and Michael addition, contributing to the synthesis of complex organic molecules.
Used in Research and Development:
(2E)-4-(Dimethylamino)but-2-enoic acid is also employed in the research and development of new materials and compounds. Its properties and reactivity make it a promising candidate for the exploration of novel chemical entities and the advancement of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 98548-82-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,8,5,4 and 8 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 98548-82:
(7*9)+(6*8)+(5*5)+(4*4)+(3*8)+(2*8)+(1*2)=194
194 % 10 = 4
So 98548-82-4 is a valid CAS Registry Number.
98548-82-4Relevant academic research and scientific papers
QUINAZOLINE DERIVATIVE AND USE THEREOF
-
Paragraph 0176; 0177; 0179; 0181; 0182; 0184, (2020/11/26)
The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.
NOVEL QUINAZOLINE DERIVATIVES
-
Page/Page column 58-59, (2011/08/03)
This disclosure concerns novel quinazoline compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful anticancer agents, especially in inhibiting the function of the EGF receptor tyrosine kinases, HERl tyrosine kinase, and HER2 tyrosine kinase. Thus, the disclosure also concerns a method of treating hyperproliferative diseases or conditions, such as various cancers and benign prostate hyperplasia (BPH), by use of these novel compounds or a composition comprising such novel compounds.
